EGFR and non-small cell lung carcinoma: These observations indicate that checkpoint inhibitors, compared with docetaxel, prolong overall survival in second-line therapy in NSCLC; the absence of benefit in OS in EGFR-mutant patients suggest that in these patients these agents may be considered only after the failure of other effective therapies.